Sort   by:  
 Page size 
UnknownFCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab.
Not available
S-EPMC4045863 | biostudies-literature
UnknownPrognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome.
Not available
S-EPMC6008450 | biostudies-literature
UnknownInterleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer.
Not available
S-EPMC5342719 | biostudies-literature
UnknownIntestinal PTGS2 mRNA levels, PTGS2 gene polymorphisms, and colorectal carcinogenesis.
Not available
S-EPMC4148233 | biostudies-literature
UnknownCetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study.
Not available
S-EPMC5482736 | biostudies-literature
UnknownSurvival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer.
Not available
S-EPMC5173107 | biostudies-literature
Sort   by:  
 Page size